Focal Inc., Johnson & Johnson Co. deal

J&J's Ethicon Inc. subsidiary received exclusive rights to commercialize Focal's synthetic

Read the full 114 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE